Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomised comparison of a biodegradable polymer ultra-thin sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients with de novo native coronary artery lesions: the meriT-V trial.
Abizaid A, Kedev S, Kedhi E, Talwar S, Erglis A, Hlinomaz O, Masotti M, Fath-Ordoubadi F, Lemos PA, Milewski K, Botelho R, Costa R, Bangalore S. Abizaid A, et al. Among authors: masotti m. EuroIntervention. 2018 Dec 7;14(11):e1207-e1214. doi: 10.4244/EIJ-D-18-00762. EuroIntervention. 2018. PMID: 30222120 Free article. Clinical Trial.
Safety and efficacy of a bioabsorbable polymer-coated, everolimus-eluting coronary stent in patients with diabetes: the EVOLVE II diabetes substudy.
Kereiakes DJ, Meredith IT, Masotti M, Carrié D, Moreno R, Erglis A, Mehta SR, Elhadad S, Berland J, Stein B, Airaksinen J, Jobe RL, Reitman A, Janssens L, Christen T, Dawkins KD, Windecker S. Kereiakes DJ, et al. Among authors: masotti m. EuroIntervention. 2017 Mar 20;12(16):1987-1994. doi: 10.4244/EIJ-D-16-00643. EuroIntervention. 2017. PMID: 27840326 Free article. Clinical Trial.
Rationale and design of the RIBS IV randomised clinical trial (drug-eluting balloons versus everolimus-eluting stents for patients with drug-eluting stent restenosis).
Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, García Del Blanco B, García-Touchard A, López-Minguéz JR, Rivero F, Masotti M, Zueco J, Cequier A, Morís C, Fernández-Ortíz A, Escaned J, Jiménez-Quevedo P, Gonzalo N, Fernández C, Macaya C; Restenosis Intra-stent: drug-eluting Balloon vs. everolimus-eluting Stent (RIBS IV) Study Investigators (under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology). Alfonso F, et al. Among authors: masotti m. EuroIntervention. 2015 Jul;11(3):336-42. doi: 10.4244/EIJY14M09_07. EuroIntervention. 2015. PMID: 25244700 Free article. Clinical Trial.
BIOFLOW-IV, a randomised, intercontinental, multicentre study to assess the safety and effectiveness of the Orsiro sirolimus-eluting stent in the treatment of subjects with de novo coronary artery lesions: primary outcome target vessel failure at 12 months.
Saito S, Toelg R, Witzenbichler B, Haude M, Masotti M, Salmeron R, Witkowski A, Uematsu M, Takahashi A, Waksman R, Slagboom T. Saito S, et al. Among authors: masotti m. EuroIntervention. 2019 Dec 6;15(11):e1006-e1013. doi: 10.4244/EIJ-D-18-01214. EuroIntervention. 2019. PMID: 31235458 Free article. Clinical Trial.
Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent.
Meredith IT, Verheye S, Weissman NJ, Barragan P, Scott D, Valdés Chávarri M, West NE, Kelbæk H, Whitbourn R, Walters DL, Kubica J, Thuesen L, Masotti M, Banning A, Sjögren I, Stables RH, Allocco DJ, Dawkins KD. Meredith IT, et al. Among authors: masotti m. EuroIntervention. 2013 Jul;9(3):308-15. doi: 10.4244/EIJV9I3A52. EuroIntervention. 2013. PMID: 23872647 Free article. Clinical Trial.
Comparison of the Efficacy of Everolimus-Eluting Stents Versus Drug-Eluting Balloons in Patients With In-Stent Restenosis (from the RIBS IV and V Randomized Clinical Trials).
Alfonso F, Pérez-Vizcayno MJ, García Del Blanco B, García-Touchard A, Masotti M, López-Minguez JR, Iñiguez A, Zueco J, Velazquez M, Cequier A, Lázaro-García R, Martí V, Moris C, Urbano-Carrillo C, Bastante T, Rivero F, Cárdenas A, Gonzalo N, Jiménez-Quevedo P, Fernández C; Restenosis Intra-Stent: Drug-Eluting Balloon vs Everolimus-Eluting Stent (RIBS-IV and V Studies) Investigators (Under the auspices of the Interventional Cardiology Working Group of the Spanish Society of Cardiology). Alfonso F, et al. Among authors: masotti m. Am J Cardiol. 2016 Feb 15;117(4):546-554. doi: 10.1016/j.amjcard.2015.11.042. Epub 2015 Dec 8. Am J Cardiol. 2016. PMID: 26725102 Clinical Trial.
Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent.
Meredith IT, Verheye S, Weissman NJ, Barragan P, Scott D, Chávarri MV, West NE, Kelbæk H, Whitbourn R, Walters DL, Kubica J, Thuesen L, Masotti M, Banning A, Sjögren I, Stables RH, Allocco DJ, Dawkins KD. Meredith IT, et al. Among authors: masotti m. EuroIntervention. 2013 May 22:20130416-02. Online ahead of print. EuroIntervention. 2013. PMID: 23688934
Comparison of paclitaxel-eluting stents (Taxus) and everolimus-eluting stents (Xience) in left main coronary artery disease with 3 years follow-up (from the ESTROFA-LM registry).
De la Torre Hernandez JM, Alfonso F, Sanchez Recalde A, Jimenez Navarro MF, Perez de Prado A, Hernandez F, Abdul-Jawad Altisent O, Roura G, Garcia Camarero T, Elizaga J, Rivero F, Gimeno F, Calviño R, Moreu J, Bosa F, Rumoroso JR, Bullones JA, Gallardo A, Fernandez Diaz JA, Ruiz Arroyo JR, Aragon V, Masotti M; ESTROFA-LM Study Group. De la Torre Hernandez JM, et al. Among authors: masotti m. Am J Cardiol. 2013 Mar 1;111(5):676-83. doi: 10.1016/j.amjcard.2012.11.019. Epub 2012 Dec 27. Am J Cardiol. 2013. PMID: 23273715 Clinical Trial.
194 results